CRISPR Therapeutics (CRSP) Set to Announce Quarterly Earnings on Monday

CRISPR Therapeutics (NASDAQ:CRSP) will likely be releasing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect CRISPR Therapeutics to post earnings of ($1.04) per share and revenue of $14.75 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%. The company had revenue of $10.18 million during the quarter. On average, analysts expect CRISPR Therapeutics to post ($4.44) EPS for the current fiscal year and ($3.60) EPS for the next fiscal year.

CRISPR Therapeutics Stock Down 0.1%

Shares of NASDAQ:CRSP opened at $51.35 on Monday. The company has a market cap of $4.96 billion, a PE ratio of -10.91 and a beta of 1.76. CRISPR Therapeutics has a 1 year low of $44.12 and a 1 year high of $64.74. The stock’s 50-day moving average is $54.19 and its 200 day moving average is $52.92. The company has a debt-to-equity ratio of 0.34, a current ratio of 17.85 and a quick ratio of 17.85.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 47,837 shares of the firm’s stock in a transaction on Monday, October 19th. The stock was sold at an average price of $49.78, for a total transaction of $2,381,325.86. Following the transaction, the chief executive officer owned 311,899 shares in the company, valued at approximately $15,526,332.22. This trade represents a 13.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel James R. Kasinger sold 10,400 shares of the company’s stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $60.24, for a total value of $626,496.00. Following the sale, the general counsel owned 94,784 shares of the company’s stock, valued at approximately $5,709,788.16. This represents a 9.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 93,558 shares of company stock worth $4,881,663 over the last quarter. 5.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have commented on CRSP shares. Citigroup restated a “market outperform” rating on shares of CRISPR Therapeutics in a report on Monday, September 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Thursday, October 15th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $55.00 target price on shares of CRISPR Therapeutics in a report on Thursday, August 6th. Wall Street Zen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, William Blair raised CRISPR Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, CRISPR Therapeutics has an average rating of “Moderate Buy” and an average target price of $65.75.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.